Independent Clonal Origin in Early‐Stage Bilateral Papillary Thyroid Cancer: Evidence From Nuclear and Mitochondrial Genome Analysis
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Xingyun Su und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Thyroid Cancer, Papillary, Thyroid Neoplasms, Genome, Mitochondrial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: This study was supported by National Natural Science Foundation of China., National Natural Science Foundation of China.
Abstract (Originalsprache)
Papillary thyroid cancer (PTC) often presents as anatomically distinct foci in bilateral lobes. However, it remains controversial whether these foci arise independently from distinct malignant progenitor cells or result from the dissemination of the primary lesion. Fifteen pairs of bilateral PTC at Stage I were enrolled, and sequencing was performed using a 437‐cancer‐gene panel (Geneseeq). The entire mitochondrial DNA (mtDNA) was also sequenced and analyzed. The genetic alterations and molecular profiles were comprehensively analyzed and compared between the paired bilateral tumors. Fourty‐eight mutations were detected in the nuclear genome, all of which were somatic and heteroplasmic. Among these, BRAF V600E mutation was predominant (25/30, 83.3%). In mtDNA, three mutations (10963A‐C, 13193T‐C, 13341 C‐G) were identified as novel, seven heteroplasmic mutations were detected including six somatic mutations. Discordant genetic alterations were observed between the paired tumors in 86.7% (13/15) of bilateral PTC cases. Our results reveal that the majority of early‐stage bilateral PTCs develop from independent malignant clones harboring different genetic backgrounds, which provides insights into the pathogenesis of bilateral PTCs and supports individualized clinical decision‐making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
- National Health Commission Key Laboratory of Combined Multiorgan Transplantation, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Weibin Wang
Förderung
- This study was supported by National Natural Science Foundation of China.
- National Natural Science Foundation of China
Zitieren
APA
Su, X., Yuan, J., Chen, X., Chen, S., Wang, X., Zhou, J., Teng, L., Zhang, F., & Wang, W. (2025). Independent Clonal Origin in Early‐Stage Bilateral Papillary Thyroid Cancer: Evidence From Nuclear and Mitochondrial Genome Analysis. Molecular Carcinogenesis. https://doi.org/10.1002/mc.70031
Vancouver
Su X, Yuan J, Chen X, Chen S, Wang X, Zhou J, et al. Independent Clonal Origin in Early‐Stage Bilateral Papillary Thyroid Cancer: Evidence From Nuclear and Mitochondrial Genome Analysis. Molecular Carcinogenesis. 2025. doi:10.1002/mc.70031
BibTeX
@article{Su2025,
author = {Su, Xingyun and Yuan, Jimeng and Chen, Xianmeng and Chen, Shitu and Wang, Xumeng and Zhou, Jie and Teng, Lisong and Zhang, Feng and Wang, Weibin},
title = {Independent Clonal Origin in Early‐Stage Bilateral Papillary Thyroid Cancer: Evidence From Nuclear and Mitochondrial Genome Analysis},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.70031}
}
EUVIMED